Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 1550396.
- Also identified by PMC identifier 1005650.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The antiphospholipid syndrome was initially described in 1986. To reassess the validity of antiphospholipid antibodies in systemic lupus erythematosus (SLE), 95 patients with SLE were studied. Their antiphospholipid antibody profile was analysed and correlated with clinical findings such as thrombosis, abortions, or thrombocytopenia. A low prevalence of these antibodies was found (13 patients; 14%) with a high specificity for thrombosis (92%) and abortions (92%). The importance of anticardiolipin antibodies as a risk factor for thrombosis or abortions, or both, in patients with SLE is reaffirmed by this work.
Medical subject headings
- Antiphospholipid Syndrome
- Lupus Erythematosus, Systemic